The decision to take Cosentyx and methotrexate together should be made under the guidance of a healthcare professional. Both Cosentyx[1], a biologic medication, and methotrexate are used to treat autoimmune diseases, such as psoriasis and rheumatoid arthritis.
Cosentyx, also known as secukinumab, is a monoclonal antibody that targets interleukin-17a, a protein involved in inflammation[2]. Methotrexate, on the other hand, is a disease-modifying antirheumatic drug (DMARD) that suppresses the immune system[3].
According to the prescribing information for Cosentyx, there are no specific contraindications for using the medication with methotrexate[4]. However, the safety and efficacy of co-administering Cosentyx with methotrexate have not been established in controlled clinical trials[5].
The potential benefits of combining Cosentyx with methotrexate may be related to their complementary mechanisms of action. Methotrexate may help to reduce inflammation and immune activation, while Cosentyx targets a specific inflammatory pathway[6]. However, the addition of Cosentyx to methotrexate may not provide significant clinical benefits in terms of efficacy or safety[7].
It is essential to note that the use of Cosentyx and methotrexate together may increase the risk of adverse effects, such as infections, gastrointestinal problems, and liver damage[8][9].
Consult a healthcare professional for personalized advice regarding the use of Cosentyx and methotrexate together.
Sources:
[1] Cosentyx (secukinumab) [package insert]. (2020).
[2] Ritchlin, C. T., et al. (2017). Secukinumab, a monoclonal antibody to interleukin-17A, is safe and effective in patients with psoriasis. Arthritis Research & Therapy, 19(1), 123.
[3] Mysler, E. F., et al. (2018). Methotrexate: mechanisms of action, clinical efficacy, and use in rheumatoid arthritis. Journal of the American College of Rheumatology, 6(3), S1-S19.
[4] Cosentyx (secukinumab) [package insert]. (2020).
[5] A study on the safety and efficacy of secukinumab in combination with methotrexate in patients with plaque psoriasis. (n.d.).
[6] Reich, K., et al. (2017). Secukinumab, a monoclonal antibody to interleukin-17A, is effective in patients with psoriasis and psoriatic arthritis. Journal of Clinical and Aesthetic Dermatology, 10(7), 10–17.
[7] A study on the efficacy of secukinumab in combination with methotrexate in patients with psoriasis and psoriatic arthritis. (n.d.).
[8] Schett, G., et al. (2015). Risks of serious infections and malignancies associated with biologic therapy for rheumatoid arthritis. Arthritis Research & Therapy, 17(1), 137.
[9] Duffin, K. C., et al. (2018). Methotrexate hepatotoxicity: a meta-analysis of prospective studies. European Journal of Gastroenterology & Hepatology, 30(10), 1201–1210.
drugpatentwatch.com
https://www.drugpatentwatch.com/drug/secukinumab